Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 27, 2022-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the resubmission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lenacapavir, an investigational,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news